Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Conditions

Adenocarcinoma of the Esophagus | Adenocarcinoma of the Gastroesophageal Junction | Stage IB Esophageal Cancer | Stage IIA Esophageal Cancer | Stage IIB Esophageal Cancer | Stage IIIA Esophageal Cancer | Stage IIIB Esophageal Cancer

What is the purpose of this trial?

This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving radiation therapy and combination chemotherapy together with or without trastuzumab is more effective in treating esophageal cancer.



Participation Guidelines

Age:
18 Years - N/A
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Cancer Institute (NCI)
Dates:
December 2010
Last Updated:
October 28, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01196390